RecruitingPhase 2NCT06934200

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels


Sponsor

Johns Hopkins University

Enrollment

32 participants

Start Date

May 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.


Eligibility

Min Age: 1 YearMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Omalizumab for people with food hypersensitivity. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOmalizumab

omalizumab injections


Locations(1)

Johns Hopkins

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06934200


Related Trials